Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders

X
Trial Profile

A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Topotecan
  • Indications Acute myeloid leukaemia; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Polycythaemia vera; Thrombocytosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2017 Results (n=95) assessing exposure-response analysis to inform the planning of a phase II trial published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 18 Mar 2017 Results assessing exposure-response analysis to inform the planning of a phase II trial, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 22 Aug 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top